Automotive Center Stack Market to Witness an Outstanding Growth by 2026

Automotive Center Stack Market: Introduction

Mechatronics is gripping the automotive sector swiftly and it has transformed the once conventional machine to an intelligent vehicle, which is useful to consumers and drivers. The use of high-end, effective electronics control modules in the automotive industry has increased its demand. Advanced electronic controls in automobiles have transformed driving experience and made the ride more comfortable and enjoyable. Moreover, electronic infotainment systems have become a basic feature among passenger cars and commercial vehicles in the automotive market today. The consumer electronics division is expected to act as one of the most prominent drivers for the overall automotive global market.

A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/13963\

The automotive center stack, in any vehicle, refers to the portion that has the controls and buttons and is primarily placed or mounted in the center of the automobile, near the driver’s seat. The automotive center stack consists of controls (for various activities) and instruments (for display), such as temperature display, music and audio system, air-conditioning and heating system, and others. Additionally, the automotive center stack system has been a significant tool for original equipment manufacturers over the years to enhance the aesthetic appeal of the automotive. Also, it is one of the latest forerunners to achieve product diversity in terms of automotive interiors among different manufacturers. The latest innovation by prominent producers in the automotive center stack system to make it more effective and attractive, is the introduction of complete packages for the consumer’s ease of operation. For instance, Apple’s new CARPLAY system enables its users to effectively use their vehicle controls to access their Apple smartphone functions, such as the navigation system, music, emails and contact numbers, among others.

A combination of gesture & electronic controls with respect to assembling a more-spontaneous HMI (human machine interface) for automobiles is expected to fuel the growth of the automotive center stack market worldwide.

Automotive Center Stack Market: Dynamics

The automotive center stack market has lot of scope in the research & development department and is coming up with new ideas and innovation. Some key automotive market players, such as Google and Apple are trying to develop driverless cars in which the center stack system will be controlled with voice and gesture controls in the near future, so that comfort is increased to a much higher level. Now, finding the correct directions while driving is much easier with a voice guiding through car speakers. Also, the automotive center stack market has increased due to development in the telecommunication sector, as smartphones can be directly linked with your automobile. In the current scenario, all automotive market giants are offering in-built GPS navigation systems and solutions, and music systems in all their cars as basic accessories, which are mounted on the automotive center stack. Increasing standard of living, with high comfort levels has brought the automotive center stack market in great demand, and this market is forecasted to grow even more rapidly in the future.

Automotive Center Stack Market: Regional Outlook

North America, Europe and the Middle East regions have a higher standard of living with luxurious lifestyles and high disposable incomes, this has led to the growth of automotive center stacks in automobiles. The people have developed a liking towards infotainment systems in their personal automobiles, thus the automotive center stack market is expected see rapid growth in all developed and developing countries in the future. Emerging economies in the APEJ region, especially India and China, will play an important role in the growth of the automotive center stack market in the coming future.

Automotive Center Stack Market: Market Participants

  • Delphi Automotive plc.
  • Methode Electronics
  • Visteon Corp.
  • Magna International Inc.
  • Faurecia S.A.
  • Hyundai Mobis Co Ltd.
  • Alps Electric Co. Ltd.
  • Johnson Controls Inc.
  • Valeo SA
  • Continental AG
  • Calsonic Kansei Corp.

Request to view Table of content @ http://www.persistencemarketresearch.com/toc/13963

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types and applications.

About Us

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

 

Contact

Persistence Market Research

305 Broadway

7th Floor, New York City,

NY 10007, United States,

USA – Canada Toll Free: 800-961-0353

Email: sales@persistencemarketresearch.com

Azure Power Wins Indian Railway’s Largest Rooftop Auction; Rooftop Portfolio Surpasses 100 MWs

NEW DELHI–(BUSINESS WIRE)–Azure Power (NYSE:AZRE), a leading solar power producer in India, announced that it has won 46 MWs of solar rooftop projects across eleven states pan India for Indian Railways. Indian Railways is the largest rail network in Asia and is owned and operated by the Government of India through the Ministry of Railways.

The power purchase agreement (PPA) will be signed with Indian Railways for their respective zones and coach factory for 25 years. The average tariff for the project is INR 4.63 (~USD 7 cents) per kWh with an additional capital incentive of INR 933.5 million (~US$ 14 million) upon commissioning

Out of the 46 MWs total allocation, 20 MWs has been allocated by Northern Railways division, 10 MWs by the Western Railways division, 10 MWs by the North-Central Railways division, 3 MWs by the North Western Railways division, and 3 MWs by the Rail Coach Factory division.

Inderpreet Wadhwa, Founder and Chief Executive Officer, Azure Power said, “Azure has superior rooftop solar power solutions for infrastructure, commercial and industrial customers in cities across India to lower their energy costs and meet their greenhouse gas (GHG) emission reduction targets. We are pleased to partner with Indian Railways in reducing their GHG emissions through deployment of solar energy at their facilities across locations pan- India.”

With this win, Azure Power rooftop solar portfolio surpassed 100 MWs across 14 states in India. Azure Power recently announced the successful installation and operation of the first phase of its rooftop solar power plant for Delhi Metro Rail Corporation (DMRC). The 14 MW project is one of the largest allocations by DMRC to a solar power company. The project covers DMRC metro stations, workshops and parking lots. Azure Power’s rooftop customers also include large commercial real estate companies, a leading global chain of premium hotels, distribution companies in smart cities, warehouses, DMRC and Delhi water supply company.

About Azure Power

Azure Power (NYSE:AZRE) is a leading solar power producer in India with a total portfolio of over 1,000 MWs across 18 states. It has developed, constructed and operated solar projects of varying sizes, from utility scale to rooftop, since its inception in 2008. Azure Power has a strong track record in delivering solar power projects, from the construction of India’s first private utility scale solar PV power plant in 2009, implementation of the first MW scale rooftop under the smart city initiative in 2013, to the largest solar plant (100 MW) under India’s National Solar Mission (NSM) policy in Jodhpur, Rajasthan. With its in-house engineering, procurement and construction expertise and advanced in-house operations and maintenance capability, Azure Power manages the entire development and operation process, providing low-cost solar power solutions to customers throughout India.

For more information, visit: www.azurepower.com

Azure Power Wins Indian Railway’s Largest Rooftop Auction; Rooftop Portfolio Surpasses 100 MWs

NEW DELHI–(BUSINESS WIRE)–Azure Power (NYSE:AZRE), a leading solar power producer in India, announced that it has won 46 MWs of solar rooftop projects across eleven states pan India for Indian Railways. Indian Railways is the largest rail network in Asia and is owned and operated by the Government of India through the Ministry of Railways.

The power purchase agreement (PPA) will be signed with Indian Railways for their respective zones and coach factory for 25 years. The average tariff for the project is INR 4.63 (~USD 7 cents) per kWh with an additional capital incentive of INR 933.5 million (~US$ 14 million) upon commissioning

Out of the 46 MWs total allocation, 20 MWs has been allocated by Northern Railways division, 10 MWs by the Western Railways division, 10 MWs by the North-Central Railways division, 3 MWs by the North Western Railways division, and 3 MWs by the Rail Coach Factory division.

Inderpreet Wadhwa, Founder and Chief Executive Officer, Azure Power said, “Azure has superior rooftop solar power solutions for infrastructure, commercial and industrial customers in cities across India to lower their energy costs and meet their greenhouse gas (GHG) emission reduction targets. We are pleased to partner with Indian Railways in reducing their GHG emissions through deployment of solar energy at their facilities across locations pan- India.”

With this win, Azure Power rooftop solar portfolio surpassed 100 MWs across 14 states in India. Azure Power recently announced the successful installation and operation of the first phase of its rooftop solar power plant for Delhi Metro Rail Corporation (DMRC). The 14 MW project is one of the largest allocations by DMRC to a solar power company. The project covers DMRC metro stations, workshops and parking lots. Azure Power’s rooftop customers also include large commercial real estate companies, a leading global chain of premium hotels, distribution companies in smart cities, warehouses, DMRC and Delhi water supply company.

About Azure Power

Azure Power (NYSE:AZRE) is a leading solar power producer in India with a total portfolio of over 1,000 MWs across 18 states. It has developed, constructed and operated solar projects of varying sizes, from utility scale to rooftop, since its inception in 2008. Azure Power has a strong track record in delivering solar power projects, from the construction of India’s first private utility scale solar PV power plant in 2009, implementation of the first MW scale rooftop under the smart city initiative in 2013, to the largest solar plant (100 MW) under India’s National Solar Mission (NSM) policy in Jodhpur, Rajasthan. With its in-house engineering, procurement and construction expertise and advanced in-house operations and maintenance capability, Azure Power manages the entire development and operation process, providing low-cost solar power solutions to customers throughout India.

For more information, visit: www.azurepower.com

Azure Power Wins Indian Railway’s Largest Rooftop Auction; Rooftop Portfolio Surpasses 100 MWs

NEW DELHI–(BUSINESS WIRE)–Azure Power (NYSE:AZRE), a leading solar power producer in India, announced that it has won 46 MWs of solar rooftop projects across eleven states pan India for Indian Railways. Indian Railways is the largest rail network in Asia and is owned and operated by the Government of India through the Ministry of Railways.

The power purchase agreement (PPA) will be signed with Indian Railways for their respective zones and coach factory for 25 years. The average tariff for the project is INR 4.63 (~USD 7 cents) per kWh with an additional capital incentive of INR 933.5 million (~US$ 14 million) upon commissioning

Out of the 46 MWs total allocation, 20 MWs has been allocated by Northern Railways division, 10 MWs by the Western Railways division, 10 MWs by the North-Central Railways division, 3 MWs by the North Western Railways division, and 3 MWs by the Rail Coach Factory division.

Inderpreet Wadhwa, Founder and Chief Executive Officer, Azure Power said, “Azure has superior rooftop solar power solutions for infrastructure, commercial and industrial customers in cities across India to lower their energy costs and meet their greenhouse gas (GHG) emission reduction targets. We are pleased to partner with Indian Railways in reducing their GHG emissions through deployment of solar energy at their facilities across locations pan- India.”

With this win, Azure Power rooftop solar portfolio surpassed 100 MWs across 14 states in India. Azure Power recently announced the successful installation and operation of the first phase of its rooftop solar power plant for Delhi Metro Rail Corporation (DMRC). The 14 MW project is one of the largest allocations by DMRC to a solar power company. The project covers DMRC metro stations, workshops and parking lots. Azure Power’s rooftop customers also include large commercial real estate companies, a leading global chain of premium hotels, distribution companies in smart cities, warehouses, DMRC and Delhi water supply company.

About Azure Power

Azure Power (NYSE:AZRE) is a leading solar power producer in India with a total portfolio of over 1,000 MWs across 18 states. It has developed, constructed and operated solar projects of varying sizes, from utility scale to rooftop, since its inception in 2008. Azure Power has a strong track record in delivering solar power projects, from the construction of India’s first private utility scale solar PV power plant in 2009, implementation of the first MW scale rooftop under the smart city initiative in 2013, to the largest solar plant (100 MW) under India’s National Solar Mission (NSM) policy in Jodhpur, Rajasthan. With its in-house engineering, procurement and construction expertise and advanced in-house operations and maintenance capability, Azure Power manages the entire development and operation process, providing low-cost solar power solutions to customers throughout India.

For more information, visit: www.azurepower.com

Azure Power Wins Indian Railway’s Largest Rooftop Auction; Rooftop Portfolio Surpasses 100 MWs

NEW DELHI–(BUSINESS WIRE)–Azure Power (NYSE:AZRE), a leading solar power producer in India, announced that it has won 46 MWs of solar rooftop projects across eleven states pan India for Indian Railways. Indian Railways is the largest rail network in Asia and is owned and operated by the Government of India through the Ministry of Railways.

The power purchase agreement (PPA) will be signed with Indian Railways for their respective zones and coach factory for 25 years. The average tariff for the project is INR 4.63 (~USD 7 cents) per kWh with an additional capital incentive of INR 933.5 million (~US$ 14 million) upon commissioning

Out of the 46 MWs total allocation, 20 MWs has been allocated by Northern Railways division, 10 MWs by the Western Railways division, 10 MWs by the North-Central Railways division, 3 MWs by the North Western Railways division, and 3 MWs by the Rail Coach Factory division.

Inderpreet Wadhwa, Founder and Chief Executive Officer, Azure Power said, “Azure has superior rooftop solar power solutions for infrastructure, commercial and industrial customers in cities across India to lower their energy costs and meet their greenhouse gas (GHG) emission reduction targets. We are pleased to partner with Indian Railways in reducing their GHG emissions through deployment of solar energy at their facilities across locations pan- India.”

With this win, Azure Power rooftop solar portfolio surpassed 100 MWs across 14 states in India. Azure Power recently announced the successful installation and operation of the first phase of its rooftop solar power plant for Delhi Metro Rail Corporation (DMRC). The 14 MW project is one of the largest allocations by DMRC to a solar power company. The project covers DMRC metro stations, workshops and parking lots. Azure Power’s rooftop customers also include large commercial real estate companies, a leading global chain of premium hotels, distribution companies in smart cities, warehouses, DMRC and Delhi water supply company.

About Azure Power

Azure Power (NYSE:AZRE) is a leading solar power producer in India with a total portfolio of over 1,000 MWs across 18 states. It has developed, constructed and operated solar projects of varying sizes, from utility scale to rooftop, since its inception in 2008. Azure Power has a strong track record in delivering solar power projects, from the construction of India’s first private utility scale solar PV power plant in 2009, implementation of the first MW scale rooftop under the smart city initiative in 2013, to the largest solar plant (100 MW) under India’s National Solar Mission (NSM) policy in Jodhpur, Rajasthan. With its in-house engineering, procurement and construction expertise and advanced in-house operations and maintenance capability, Azure Power manages the entire development and operation process, providing low-cost solar power solutions to customers throughout India.

For more information, visit: www.azurepower.com

2017 RBC Top 25 Canadian Immigrant Awards

TORONTO, ON–(Marketwired – March 30, 2017) – Canadian Immigrant magazine has opened the online voting phase for its ninth annual RBC Top 25 Canadian Immigrant Awards. This coveted award recognizes and celebrates the untold stories of Canadian immigrants who have made a significant contribution to Canada — all the more poignant this year as we celebrate Canada 150. The award program is proudly supported by title sponsor RBC Royal Bank. The public can now vote for up to three of their favourite finalists online at www.canadianimmigrant.ca/rbctop25 until May 22, 2017.

Our past winners have been examples of true nation builders, from entrepreneurs to artists, academics, community volunteers, sports heroes, philanthropists, inventors and visionaries, from across Canada. Their reasons, circumstances and timing for coming to Canada are as varied as their backgrounds — some fled strife in their home countries, while others chose to gain higher education; some arrived as young children, while others arrived as adults with only a few hundred dollars in their pocket.

No matter their roots, each of the winners’ stories shares a common thread: an individual rose to a challenge and used that opportunity to make Canada a better place for all. This year is no different.

„At a time when Canada’s position as a global leader in diversity and immigration is more important than ever, these awards are a symbol of what Canada is about. It is a country that has been shaped by immigration, from early settlers to today’s modern immigrants,” says Margaret Jetelina, editor of Canadian Immigrant. „We are so pleased to provide such positive examples of immigrants and their contributions to their adopted land.”

The hundreds of nominations received were reviewed by a judging panel composed of past winners. The entries were narrowed to a shortlist of 75 finalists who represent diverse ethnic communities, cities and industries across Canada.

„The RBC Top 25 Immigrant Awards celebrate the unique and diverse makeup of Canada by profiling some truly inspirational newcomers who themselves have made their mark in Canada,” said Ivy Chiu, Senior Director, Cultural Markets, RBC. „The voting period is now open online, and we welcome you to cast your vote to recognize the determination and courage from Canada’s newcomers, including a new opportunity to recognize an exemplary youth newcomer, too. So many newcomers are worthy of the spotlight, and we’re excited to shine a light on the 25 who have made a positive impact in our communities.”

For the third year, title sponsor RBC will also recognize one of the 25 winners who demonstrate excellence in business with the RBC Entrepreneur Award. In honour of Canada’s 150th, we are also introducing the Youth Award which will recognize the achievements of immigrant youth (between ages 15 and 30) who are making a difference in their adopted country through achievement and/or service, and show great potential in further building this nation demonstrating that when we invest in youth great things can happen. Similar to our RBC Entrepreneur Award, the Youth Award will be an additional honour given to one of the RBC Top 25 winners. No separate votes are required.

The award winners will be announced on June 27, 2017. They will be recognized on www.canadianimmigrant.ca and in Canadian Immigrant magazine. Each winner will also receive a commemorative plaque and $500 toward a charity of their choice provided by RBC. This year’s media partners are the Toronto Star, Metro Newspaper, CBC Toronto, Sing Tao and South Asian Focus.

About Canadian Immigrant and canadianimmigrant.ca

Attracting more than 400,000 readers each month and over 100,000 visitors every month online, Canadian Immigrant is distributed in Toronto, Vancouver and Calgary and helps new Canadians build a successful life and home in Canada. Our mandate to arrive, succeed and inspire — provides content for newcomers looking for information on careers, education and settling-in to culture and business. Our website, canadianimmigrant.ca, offers daily editorial, forums, tools and resources to help newcomers across Canada. Canadian Immigrant is a division of Metroland Media Group Limited, a dynamic media company with more than 100 community and daily newspapers in print and online, as well as innovative websites including wheels.ca, goldbook.ca, flyerland.ca, Travelalerts.ca and localwork.ca.

ABOUT RBC

Royal Bank of Canada is Canada’s largest bank, and one of the largest banks in the world, based on market capitalization. We are one of North America’s leading diversified financial services companies, and provide personal and commercial banking, wealth management, insurance, investor services and capital markets products and services on a global basis. We have over 80,000 full- and part-time employees who serve more than 16 million personal, business, public sector and institutional clients through offices in Canada, the U.S. and 35 other countries. For more information, please visit http://www.rbc.com/.‎

RBC helps communities prosper, supporting a broad range of community initiatives through donations, community investments and employee volunteer activities. For more information please see: http://www.rbc.com/community-sustainability/.

Image Available: http://www.marketwire.com/library/MwGo/2017/3/28/11G134415/Images/cimlogo-ef68405d4087849383d3fd3dc7eeae03.jpg

Signing of Japanese ODA Loan Agreement with Côte d’Ivoire: Construction of a cereal berth at Abidjan Port, the gateway to West Africa, in order to contribute to improved logistics and food security of the region

On March 30, the Japan International Cooperation Agency (JICA) signed a loan agreement with the Government of Côte d’Ivoire in Abidjan to provide a Japanese ODA loan of up to 10.869 billion yen for the Abidjan Port Cereal Berth Construction Project.

The project is to construct a new cereal berth at Abidjan Port, which functions as the gateway to West Africa, with the objectives of meeting the growing demand for rice and other cereals in Côte d’Ivoire and landlocked countries in the Sahel region, such as Burkina Faso and Mali, and improving logistics in the region. The loan funds will be allocated to civil works, such as extending of the quay, dredging, and constructing related facilities, to procuring equipment and to consulting services (such as bidding assistance and construction supervision).

The Special Terms for Economic Partnership (STEP) [1] will apply to the Japanese ODA loans for this project. Japanese technology, such as steel pipe sheet piles, is planned to be utilized to mitigate weak ground conditions and the deep dredging depth.

Located in Abidjan, which functions as the de facto capital of Côte d’Ivoire, Abidjan Port handles the biggest volume of bulk cargo in Sub-Saharan Africa and the biggest volume of container cargo in West Africa. Located at the starting point of international corridors and railways the port also plays a role as the gateway to Mali, Burkina Faso, Niger and other hinterland countries of the Sahel region, serving as as a hub for logistics in the region.

Since the 1980s, there has been no new investment in Port Abidjan due to economic and governmental turmoil, and the infrastructure has not kept pace with the increasing demand for cargo in conjunction with the rising population and economic growth in Côte d’Ivoire and the surrounding Sahel countries. The quay structure and waterway depth, in particular, have not kept up with the increasing size of ships, and deterioration of the existing infrastructure has prevented the cargo volume to grow since 2008. Currently at over 70 percent, the berth occupancy rate [2] at Port Abidjan is projected to reach 80 percent, the physical limit, in 2018, and one of the three existing piers currently used for cereal will become unavailable due to the construction of another container berth. The construction of a new cereal berth is therefore considered to be a priority.

By constructing a new cereal berth, the project is expected to nearly double the average loading capacity of cereal cargo, and to reduce the berth occupancy to approximately 60 percent. It is also expected that the project will meet the growing demand for cereals in Côte d’Ivoire and the surrounding Sahel countries while stimulating the economy and contributing to food security.

Alongside with this project, the Project for the Improvement of the Japan-Ivorian Friendship Intersection, a grant aid cooperation project to construct flyover intersections for the main roads in Abidjan, is underway. This grant aid project is expected to contribute to smooth traffic starting from the Port of Abidjan towards the city center and outskirts, and contribute to more efficient logistics within Côte d’Ivoire and nearby countries.

1: STEP is special assistance terms for promoting the visibility of Japanese aid through a transfer of outstanding Japanese technology and expertise to developing nations. The main contract is Japan tied and subcontracting is general untied. Although the main contract allows a joint venture with the borrowing country, a Japanese company must be the leading partner in such an arrangement.

2: The percentage in terms of the amount of time when ships are using the berth.

1. Terms and Amount of Loan

Project title Amount (million yen) Annual interest rate (%) Repayment
period
(years)
Grace
period
(years)
Procurement
Project Consulting services
Abidjan Port Cereal Berth Construction Project 10,869 0.10 0.01 40 10 Japan tied

Note: Special Terms for Economic Partnership (STEP) apply.

2. Executing Agency
Autonomous Port of Abidjan
Address: BP V 85, Abidjan, Côte d’Ivoire
Phone: +225-21-23-81-01/02, fax: +225-21-34-02-62

3. Planned Implementation Schedule
(1) Completion of project: September 2020 – when the facilities are put into service
(2) Issuing of letters of invitation for consulting services (including construction supervision):
November 2017
(3) Tender announcement of initial procurement package for international competitive bidding on project construction:
Procurement package title: Cereal Berth Construction Package
Planned release date: December 2017

4. JICA Contact Information
For further information about the procurement schedule, please contact the party listed below.
Africa Division 4, Africa Department, JICA
Address: Nibancho Center Building 5-25, Niban-cho, Chiyoda-ku, Tokyo 102-8012, JAPAN
Phone: +81-3-5226-8294, fax: +81-3-5226-6363

Progenics Pharmaceuticals Announces Positive Topline Results from Registrational Phase 2b Trial of AZEDRA®

– Novel, targeted radiotherapeutic for malignant and/or recurrent pheochromocytoma and paraganglioma –
– Study achieves primary endpoint –– Secondary endpoint shows favorable tumor response to therapy –– Company to submit NDA in mid-2017 –-Conference call at 8:30 a.m. Eastern Time today –NEW YORK, March 30, 2017 (GLOBE NEWSWIRE) — Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced that the Company’s registrational Phase 2b trial of its novel radiotherapeutic candidate, AZEDRA® (iobenguane I 131) Injection, has achieved its primary endpoint. The open-label, multi-center study was conducted under a Special Protocol Assessment (SPA) agreement with the Food and Drug Administration (FDA). The trial was designed to evaluate the efficacy and safety of AZEDRA in patients with malignant and/or recurrent pheochromocytoma or paraganglioma, which are rare neuroendocrine tumors. There are currently no approved therapeutics in the U.S. for the treatment of malignant and/or recurrent pheochromocytoma or paraganglioma. AZEDRA has received Breakthrough Therapy, Orphan Drug and Fast Track designations from the FDA.The study met the primary endpoint evaluating the proportion of patients who achieved a 50% or greater reduction of all antihypertensive medication for at least six months. Under the study protocol, the primary endpoint is achieved if the lower limit of the two-sided 95% confidence interval was above 10%.In the trial, 17 (25%) of the 68 evaluable patients experienced a 50% or greater reduction of all antihypertensive medication for at least 6 months.  The lower limit of the 95% confidence interval was 16.15%, thus meeting the primary endpoint.  The upper limit of the 95% confidence interval was 36.52%.Progenics also reported favorable data from a key secondary endpoint, the proportion of patients with overall tumor response as measured by Response Evaluation Criteria In Solid Tumors (RECIST) criteria.  In this highly pre-treated patient population, 92.2% of patients who received at least one AZEDRA therapeutic dose achieved partial response or stable disease.“The positive data from this trial are clinically meaningful and provide compelling evidence for the use of AZEDRA to treat malignant and/or recurrent pheochromocytoma and paraganglioma,” said Dr. Daniel Pryma, Associate Professor of Radiology & Radiation Oncology and Chief, Division of Nuclear Medicine & Clinical Molecular Imaging at the Perelman School of Medicine at the University of Pennsylvania, the trial’s lead investigator. “Without any approved therapeutics in the U.S. for these rare and devastating life-threatening tumors, patients face a poor prognosis and few options. The tumor response data, in particular for the patients that received two doses, along with the adverse event profile from this trial, suggest that AZEDRA has the potential to be a true breakthrough in addressing these difficult-to-treat patients.”Phase 2b Trial Topline Results
The Phase 2b open-label trial was designed to evaluate the efficacy and safety of two therapeutic doses of AZEDRA administered three months apart to patients with malignant relapsed/refractory pheochromocytoma or paraganglioma.
Primary Endpoint: Reduction in Antihypertensive Medications
Under the study protocol, the primary endpoint is achieved if the lower limit of the two-sided 95% confidence interval was above 10%.  In order to achieve this primary endpoint, a minimum of 12 of the total 68 evaluable patients must have a 50% or greater reduction of all antihypertensive medication for at least 6 months.  As shown in the table below, 17 patients responded, giving a lower limit of the 95% confidence interval of 16.15%, thus meeting the primary endpoint.

Secondary Endpoint: Overall Tumor Response Assessment per RECIST Criteria
Best response over 12 months after first therapeutic dose
*4 patients did not have follow-up scansAZEDRA was generally well tolerated. The most common treatment emergent adverse events were nausea, thrombocytopenia, anemia, fatigue, leukopenia, and neutropenia.  These events are consistent with those observed in prior AZEDRA studies.“We intend to move quickly to complete our New Drug Application submission by mid-2017, as these topline results underscore the potential of AZEDRA in this ultra-orphan indication,” said Mark Baker, Chief Executive Officer of Progenics. “We are grateful to the patients and investigators who participated in this trial, and are committed to bringing a new treatment option to this rare cancer population.”Progenics plans to present additional data from this trial at a medical meeting in the second half of 2017.Conference Call and Webcast
Progenics will further review these topline results from the registrational Phase 2b trial of AZEDRA® in a conference call today at 8:30 a.m. ET. To participate, please dial (877) 250-8889 (domestic) or (720) 545-0001 (international) and reference conference ID 99400682. A live webcast will be available in the Media Center of the Progenics website, www.progenics.com, and a replay will be available there for two weeks.
About AZEDRA®AZEDRA® (iobenguane I 131) Injection, a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands, respectively. AZEDRA has been granted Breakthrough Therapy and Orphan Drug designations, as well as Fast Track status in the U.S. Under a SPA agreement with the U.S. Food and Drug Administration (FDA), a Phase 2 registrational study has been completed in patients with malignant and/or recurrent pheochromocytoma and paraganglioma.  There are currently no FDA-approved therapies for the treatment of these ultra-orphan diseases.About Pheochromocytoma and ParagangliomaPheochromocytoma and paraganglioma are rare neuroendocrine tumors that arise from cells of the sympathetic nervous system. When pheochromocytomas are located outside the adrenal glands, they are called paragangliomas. Standard treatment options for these tumors include surgery, palliative therapy and symptom management. Pheochromocytoma and paraganglioma tumors frequently secrete high levels of hormones that can lead to life threatening hypertension, heart failure, and stroke in these patients.  Malignant and recurrent pheochromocytoma and paraganglioma may result in unresectable disease with a poor prognosis, representing a significant management challenge with very limited treatment options and no approved anti-tumor therapies.About ProgenicsProgenics Pharmaceuticals, Inc. develops innovative medicines and other technologies to target and treat cancer. The Company’s pipeline includes: 1) therapeutic agents designed to precisely target cancer (AZEDRA® and 1095), 2) PSMA-targeted imaging agents for prostate cancer (1404 and PyLTM), and 3) imaging analysis tools. Progenics’ first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with Valeant Pharmaceuticals International, Inc.This press release may contain projections and other „forward-looking statements” regarding future events. Statements contained in this communication that refer to Progenics’ estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Progenics’ current perspective of existing trends and information as of the date of this communication. Forward looking statements generally will be accompanied by words such as „anticipate,” „believe,” „plan,” „could,” „should,” „estimate,” „expect,” „forecast,” „outlook,” „guidance,” „intend,” „may,” „might,” „will,” „possible,” „potential,” „predict,” „project,” or other similar words, phrases or expressions. Such statements are predictions only, and are subject to risks and uncertainties that could cause actual events or results to differ materially. These risks and uncertainties include, among others, the cost, timing and unpredictability of results of clinical trials and other development activities and collaborations, such as our collaboration with Valeant on the RELISTOR oral formulation and the Phase 3 clinical program for 1404; our ability to successfully integrate EXINI Diagnostics AB and to develop and commercialize its products; the unpredictability of the duration and results of regulatory review of New Drug Applications and Investigational NDAs; market acceptance for approved products; the effectiveness of the efforts of our partners to market and sell products on which we collaborate and the royalty revenue generated thereby; generic and other competition; the possible impairment of, inability to obtain and costs of obtaining intellectual property rights; possible product safety or efficacy concerns, general business, financial and accounting matters, litigation and other risks. More information concerning Progenics and such risks and uncertainties is available on its website, and in its press releases and reports it files with the U.S. Securities and Exchange Commission. Progenics is providing the information in this press release as of its date and, except as expressly required by law, Progenics disclaims any intent or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances or otherwise.Additional information concerning Progenics and its business may be available in press releases or other public announcements and public filings made after this release. For more information, please visit www.progenics.com. Please follow us on LinkedIn®. Information on or accessed through our website or social media sites is not included in the company’s SEC filings.(PGNX-F)Contact:

Melissa Downs
Investor Relations
(646) 975-2533
mdowns@progenics.com

Progenics Pharmaceuticals Announces Positive Topline Results from Registrational Phase 2b Trial of AZEDRA®

– Novel, targeted radiotherapeutic for malignant and/or recurrent pheochromocytoma and paraganglioma –
– Study achieves primary endpoint –– Secondary endpoint shows favorable tumor response to therapy –– Company to submit NDA in mid-2017 –-Conference call at 8:30 a.m. Eastern Time today –NEW YORK, March 30, 2017 (GLOBE NEWSWIRE) — Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced that the Company’s registrational Phase 2b trial of its novel radiotherapeutic candidate, AZEDRA® (iobenguane I 131) Injection, has achieved its primary endpoint. The open-label, multi-center study was conducted under a Special Protocol Assessment (SPA) agreement with the Food and Drug Administration (FDA). The trial was designed to evaluate the efficacy and safety of AZEDRA in patients with malignant and/or recurrent pheochromocytoma or paraganglioma, which are rare neuroendocrine tumors. There are currently no approved therapeutics in the U.S. for the treatment of malignant and/or recurrent pheochromocytoma or paraganglioma. AZEDRA has received Breakthrough Therapy, Orphan Drug and Fast Track designations from the FDA.The study met the primary endpoint evaluating the proportion of patients who achieved a 50% or greater reduction of all antihypertensive medication for at least six months. Under the study protocol, the primary endpoint is achieved if the lower limit of the two-sided 95% confidence interval was above 10%.In the trial, 17 (25%) of the 68 evaluable patients experienced a 50% or greater reduction of all antihypertensive medication for at least 6 months.  The lower limit of the 95% confidence interval was 16.15%, thus meeting the primary endpoint.  The upper limit of the 95% confidence interval was 36.52%.Progenics also reported favorable data from a key secondary endpoint, the proportion of patients with overall tumor response as measured by Response Evaluation Criteria In Solid Tumors (RECIST) criteria.  In this highly pre-treated patient population, 92.2% of patients who received at least one AZEDRA therapeutic dose achieved partial response or stable disease.“The positive data from this trial are clinically meaningful and provide compelling evidence for the use of AZEDRA to treat malignant and/or recurrent pheochromocytoma and paraganglioma,” said Dr. Daniel Pryma, Associate Professor of Radiology & Radiation Oncology and Chief, Division of Nuclear Medicine & Clinical Molecular Imaging at the Perelman School of Medicine at the University of Pennsylvania, the trial’s lead investigator. “Without any approved therapeutics in the U.S. for these rare and devastating life-threatening tumors, patients face a poor prognosis and few options. The tumor response data, in particular for the patients that received two doses, along with the adverse event profile from this trial, suggest that AZEDRA has the potential to be a true breakthrough in addressing these difficult-to-treat patients.”Phase 2b Trial Topline Results
The Phase 2b open-label trial was designed to evaluate the efficacy and safety of two therapeutic doses of AZEDRA administered three months apart to patients with malignant relapsed/refractory pheochromocytoma or paraganglioma.
Primary Endpoint: Reduction in Antihypertensive Medications
Under the study protocol, the primary endpoint is achieved if the lower limit of the two-sided 95% confidence interval was above 10%.  In order to achieve this primary endpoint, a minimum of 12 of the total 68 evaluable patients must have a 50% or greater reduction of all antihypertensive medication for at least 6 months.  As shown in the table below, 17 patients responded, giving a lower limit of the 95% confidence interval of 16.15%, thus meeting the primary endpoint.

Secondary Endpoint: Overall Tumor Response Assessment per RECIST Criteria
Best response over 12 months after first therapeutic dose
*4 patients did not have follow-up scansAZEDRA was generally well tolerated. The most common treatment emergent adverse events were nausea, thrombocytopenia, anemia, fatigue, leukopenia, and neutropenia.  These events are consistent with those observed in prior AZEDRA studies.“We intend to move quickly to complete our New Drug Application submission by mid-2017, as these topline results underscore the potential of AZEDRA in this ultra-orphan indication,” said Mark Baker, Chief Executive Officer of Progenics. “We are grateful to the patients and investigators who participated in this trial, and are committed to bringing a new treatment option to this rare cancer population.”Progenics plans to present additional data from this trial at a medical meeting in the second half of 2017.Conference Call and Webcast
Progenics will further review these topline results from the registrational Phase 2b trial of AZEDRA® in a conference call today at 8:30 a.m. ET. To participate, please dial (877) 250-8889 (domestic) or (720) 545-0001 (international) and reference conference ID 99400682. A live webcast will be available in the Media Center of the Progenics website, www.progenics.com, and a replay will be available there for two weeks.
About AZEDRA®AZEDRA® (iobenguane I 131) Injection, a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands, respectively. AZEDRA has been granted Breakthrough Therapy and Orphan Drug designations, as well as Fast Track status in the U.S. Under a SPA agreement with the U.S. Food and Drug Administration (FDA), a Phase 2 registrational study has been completed in patients with malignant and/or recurrent pheochromocytoma and paraganglioma.  There are currently no FDA-approved therapies for the treatment of these ultra-orphan diseases.About Pheochromocytoma and ParagangliomaPheochromocytoma and paraganglioma are rare neuroendocrine tumors that arise from cells of the sympathetic nervous system. When pheochromocytomas are located outside the adrenal glands, they are called paragangliomas. Standard treatment options for these tumors include surgery, palliative therapy and symptom management. Pheochromocytoma and paraganglioma tumors frequently secrete high levels of hormones that can lead to life threatening hypertension, heart failure, and stroke in these patients.  Malignant and recurrent pheochromocytoma and paraganglioma may result in unresectable disease with a poor prognosis, representing a significant management challenge with very limited treatment options and no approved anti-tumor therapies.About ProgenicsProgenics Pharmaceuticals, Inc. develops innovative medicines and other technologies to target and treat cancer. The Company’s pipeline includes: 1) therapeutic agents designed to precisely target cancer (AZEDRA® and 1095), 2) PSMA-targeted imaging agents for prostate cancer (1404 and PyLTM), and 3) imaging analysis tools. Progenics’ first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with Valeant Pharmaceuticals International, Inc.This press release may contain projections and other „forward-looking statements” regarding future events. Statements contained in this communication that refer to Progenics’ estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Progenics’ current perspective of existing trends and information as of the date of this communication. Forward looking statements generally will be accompanied by words such as „anticipate,” „believe,” „plan,” „could,” „should,” „estimate,” „expect,” „forecast,” „outlook,” „guidance,” „intend,” „may,” „might,” „will,” „possible,” „potential,” „predict,” „project,” or other similar words, phrases or expressions. Such statements are predictions only, and are subject to risks and uncertainties that could cause actual events or results to differ materially. These risks and uncertainties include, among others, the cost, timing and unpredictability of results of clinical trials and other development activities and collaborations, such as our collaboration with Valeant on the RELISTOR oral formulation and the Phase 3 clinical program for 1404; our ability to successfully integrate EXINI Diagnostics AB and to develop and commercialize its products; the unpredictability of the duration and results of regulatory review of New Drug Applications and Investigational NDAs; market acceptance for approved products; the effectiveness of the efforts of our partners to market and sell products on which we collaborate and the royalty revenue generated thereby; generic and other competition; the possible impairment of, inability to obtain and costs of obtaining intellectual property rights; possible product safety or efficacy concerns, general business, financial and accounting matters, litigation and other risks. More information concerning Progenics and such risks and uncertainties is available on its website, and in its press releases and reports it files with the U.S. Securities and Exchange Commission. Progenics is providing the information in this press release as of its date and, except as expressly required by law, Progenics disclaims any intent or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances or otherwise.Additional information concerning Progenics and its business may be available in press releases or other public announcements and public filings made after this release. For more information, please visit www.progenics.com. Please follow us on LinkedIn®. Information on or accessed through our website or social media sites is not included in the company’s SEC filings.(PGNX-F)Contact:

Melissa Downs
Investor Relations
(646) 975-2533
mdowns@progenics.com

Pre Close Trading Statement

30 March 2017

 

 

RPC Group Plc

 

Pre Close Trading Statement

 

RPC Group Plc („RPC” or the „Group”), a leading plastic products design and engineering company for both packaging and selected non-packaging markets, today issues a pre close trading statement for the financial year ending 31 March 2017 ahead of its full year results announcement, due to be published on 7 June 2017.

 

 

Trading performance

 

Revenues for the financial year 2016/2017 are anticipated to be significantly ahead of last year, reflecting contributions from acquisitions and continued underlying organic growth. The Group’s overall performance has been encouraging with the adjusted operating profit for the year ahead of management expectations.

 

The Group’s financial position remains robust with good cash flow development. The net proceeds of the rights issue announced on 9 February 2017 have been received and following completion of the Letica acquisition the Group retains significant headroom under its debt facilities, which include a new US$750 million multi-currency term loan facility.

 

 

Acquisitions and integration update

 

The larger acquisitions of GCS (completed March 2016) and BPI (completed August 2016) have integrated well and are performing ahead of expectations. Key management has been retained with GCS operating as a Strategic Business Unit („SBU”) in the Bramlage division and BPI as a stand-alone division.

 

With respect to the other previously announced acquisitions, the following update can be given:  

 

·     the acquisition of ESE completed on 31 January and accordingly is anticipated to make a contribution to the 2016/17 financial year. The company is operating as a stand-alone SBU in the Promens division and early purchasing synergies have already been realised;

·     the acquisition of Letica Group completed on the 10 March. With an EBITDA of US$67m realised in the calendar year 2016, the upfront consideration of US$490m paid for the business represents an 7.3x EBITDA multiple. Letica management are being retained and it will operate as a stand-alone SBU within the Superfos Division.  The limited Integration work required is already under way;

·     the acquisition of Astrapak Limited is expected to be completed in June with the CEO and the executive management team being retained.

 

 

Commenting on the performance, Pim Vervaat, RPC’s Chief Executive, said:

 

„I am pleased with the Group’s trading performance during the year and the successful integration of the acquired businesses. The board will continue to implement the Vision 2020 focused growth strategy, in which leading design and engineering capabilities create value in chosen market segments. At the same time the Group is looking to grow selectively in a consolidating industry whilst further enhancing its strategic buying position.”

 

 

 

For further information:

 

RPC Group Plc:

+44 (0)1933 410064

Pim Vervaat, Chief Executive

Simon Kesterton, Group Finance Director

FTI Consulting:

+44 (0)20 3727 1340

Richard Mountain

Nick Hasell